Swedish Orphan Biovitrum AB (Sobi) has restructured and extended an agreement with Exelixis, Inc. to December 31, 2019. Sobi is responsible for the commercialization and distribution of Cometriq® (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia and Turkey. The collaboration originated in February 2013, and was scheduled to expire December 31, 2015.
NNIT has signed an extension of its infrastructure outsourcing agreement with Novo Nordisk. The estimated total value of the agreement amounts to approximately DKK 1bn and covers global services, including support and maintenance of Novo Nordisk’s corporate IT infrastructure. The agreement covers Novo Nordisk’s global IT infrastructure and further supports…
Beactica Therapeutics and Oscotec, a Korean drug development company, have announced a new research development and licensing agreement. The two companies will initially jointly collaborate concerning research and early preclinical development of novel anticancer drug candidates arising out of Beactica’s LSD1 programme. Oscotec may thereafter opt to take full responsibility…
Nuevolution A/S has announced that it has entered an exclusive license agreement with a subsidiary of Merck & Co., Inc. The agreement involves small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development. Under terms of the agreement, Merck will gain exclusive rights…
The company has announced two exclusive license agreements with The University of Texas MD Anderson Cancer Center related to MAGE-A4 and VGLL1 targeting allogeneic “off-the-shelf” TCR-NK cell therapies for the treatment of various solid cancers. Under the agreements Zelluna will have exclusive rights from MD Anderson to use characterized TCRs…
